Company attributes
Other attributes
Neurocrine Biosciences is a biopharmaceutical company based in San Diego, California, United States. The company was founded on January 1, 1992 and is currently active. Neurocrine Biosciences is a public company listed on the Nasdaq stock exchange under the ticker symbol NBIX. The company operates in the biomedical engineering, pharmaceutical industry, and biotechnology sectors, focusing on Parkinson's disease and other neurological disorders.
The CEO of Neurocrine Biosciences is Kevin C. Gorman, and the CFO is Matthew C. Abernethy. The company's board of directors includes William H. Rastetter, Richard F. Pops, Shalini Sharp, Gary A. Lyons, Stephen Sherwin, and Leslie V. Norwalk.
Neurocrine Biosciences has received a total funding amount of $10,000,000 USD. The latest funding round took place on December 17, 2009. The company's investors include Venrock.
The company has a workforce of 1,100 employees and operates in a business-to-business (B2B) model. Neurocrine Biosciences has been assigned 51 patents and is headquartered at 12780 El Camino Real, San Diego, CA 92130, United States.
Neurocrine Biosciences has an official website at http://neurocrine.com and is active on social media platforms such as Twitter and LinkedIn.
